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Hereditary erythrocytosis and thrombocytosis 
with an autosomal-dominant pattern are linked 
to mutations in the erythropoietin or thrombo-
poietin (TPO; MPL) receptors (de la Chapelle 
et al., 1993; Kralovics et al., 1997; Ding et al., 
2004), respectively, or to a dysregulation of the   
synthesis of these two cytokines (Wiestner et al., 
1998). These syndromes differ from classical 
myeloproliferative disorders (MPDs) by the 
low incidence of early and late complications. 
They recapitulate the chronic administration   
of recombinant growth factors (i.e., TPO and   
erythropoietin). The G-CSF receptor (G-CSF-R)   
is also a type I cytokine receptor that binds 
G-CSF, the main cytokine that regulates granu-
lopoiesis. G-CSF-R activation by G-CSF not 
only induces proliferation and differentiation of 
neutrophils but also mobilizes BM hematopoi-
etic progenitors cells to blood (Panopoulos and 
Watowich, 2008). In this report, we identified 
a familial chronic neutrophilia caused by an   
autosomal-dominant  CSF3R  gene  mutation 
that constitutively activates G-CSF-R.
RESULTS AND DISCUSSION
We studied a three-generation Caucasian pedi-
gree (aged 8–80 yr; Fig. 1 A) in which 12 out 
of 16 individuals (6 males and 6 females) pre-
sented with a chronic neutrophilia associated 
with splenomegaly. The disorder was discov-
ered in patient 15 during a unique episode of 
systemic inflammatory response syndrome that 
combined fever, tachycardia, dyspnea, pleural 
and pericardial effusion, hepatosplenomegaly, 
and weight loss. Biological features associated 
increased WBC counts by 102,000 cells/mm3, 
with  75%  segmented  neutrophils  and  20%   
immature granulocytes, the hemoglobin level   
by 10 g/dl, and the platelet count by 101,000 
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We identify an autosomal mutation in the CSF3R gene in a family with a chronic neutro-
philia. This T617N mutation energetically favors dimerization of the granulocyte colony-
stimulating factor (G-CSF) receptor transmembrane domain, and thus, strongly promotes 
constitutive activation of the receptor and hypersensitivity to G-CSF for proliferation and 
differentiation, which ultimately leads to chronic neutrophilia. Mutant hematopoietic stem 
cells yield a myeloproliferative-like disorder in xenotransplantation and syngenic mouse 
bone marrow engraftment assays. The survey of 12 affected individuals during three  
generations indicates that only one patient had a myelodysplastic syndrome. Our data thus 
indicate that mutations in the CSF3R gene can be responsible for hereditary neutrophilia 
mimicking a myeloproliferative disorder.
© 2009 Plo et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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(14 out of 20). A fluorescent in situ hybridization analysis did 
not show evidence of EVI1 rearrangement (De Melo et al., 
2008). To eliminate a transcriptional activation of EVI1, we 
performed quantitative real-time PCR (qRT-PCR). A 30% 
decrease in EVI1 mRNA was detected (Fig. S1), suggesting 
that the deletion includes this gene.
Familial history showed that 12 out of 16 members had a 
chronic neutrophilia. There was no evidence of consanguin-
ity in this pedigree. In the 12 patients, median WBC counts 
were 21,350 cells/mm3 (range: 14,900–32,800 cells/mm3) in 
peripheral blood, with >70% segmented neutrophils or band 
cells and <10% immature granulocytes. Median neutro-
phil counts were 16,900 cells/mm3 (range: 11,000–23,700 
cells/mm3. BM analysis revealed an increase in granulocyte 
precursors without an excess of blasts. Karyotype was normal. 
Bcr-Abl transcripts and JAK2V617F were not detected. After 
this episode, patient 15 returned to chronic neutrophilia, but 
18 mo later, he developed a myelodysplastic syndrome (re-
fractory anemia with an excess of blasts type I) associating 
pancytopenia (hemoglobin, 8.1 g/dl; platelets, 41,000 cells/mm3; 
800 polymorphs per mm3 along with 12% of circulating im-
mature granulocytes), skin infiltration by mature granulo-
cytes, and 9% BM blasts. BM aspirate examination also showed 
a marked dysgranulopoiesis but no dyserythropoiesis or dys-
megakaryopoiesis. A clonal abnormality (del 3q26) was de-
tected by a conventional cytogenetic in 70% of the metaphases 
Figure 1.  An inherited mutation in the CSF3R gene in a familial neutrophilia. (A) Pedigree of the family. The black symbols represent affected indi-
viduals with neutrophilia and T617N amino acid substitution. The gray symbols represent individuals for whom clinical information was not available.  
The white symbols represent nonaffected individuals. The genotype is also indicated (N/N, normal subjects; N/M, heterozygous patients). (B) Examples of 
electrophoregrams from normal subjects or patient 15 DNA (T617N). (C–E) Liquid culture of CD34+ cells in the presence of SCF plus G-CSF or SCF (C and D) 
from controls (n = 5) or patients (n = 2, patients 7 and 15) in which three independent experiments were performed for each patient. Error bars represent  
means ± SD. *, P < 0.05. (E) Cytological examination at day 21 of culture. Numbers indicate the percentages of mature granulocytic cells. Results are representative 
of controls (n = 3) or patients (n = 2, patients 7 and 15) in which two independent experiments were performed for each patient. (F) Western blot analysis  
of P-Jak2, P-STAT3, P-STAT5, P-ERK p42-p44, and P-AKT antibodies in normal or patient CD34+ cells stimulated by G-CSF in the presence or not of AZ1480. 
Results are representative of three independent experiments either with control or patient 15. Black lines indicate that intervening lanes have been spliced out.JEM VOL. 206, August 3, 2009  1703
BRIEF DEFINITIVE REPORT
mutation associated with hereditary or acquired thrombocy-
themia (Ding et al., 2004; Chaligne et al., 2008). To evaluate 
the influence of the T617N mutation on TM helix interactions 
in the G-CSF-R, conformational searches were performed to 
identify low energy dimer conformations (Adams et al., 1996). 
For the wild-type G-CSF-R sequence, the lowest energy di-
mer structure that emerged from the searches had a symmetric 
orientation of the TM helices with Thr617 in the interface. 
The lowest energy structures of T617N G-CSF-R dimers had 
the same helix orientation, but with substantially lower inter-
action energies (wild-type, approximately 69 kcal/mol; T617N 
mutant, approximately 81 kcal/mol; Fig. 2). These compu-
tational data strongly support the notion that Asn617 stabilizes 
an active dimeric orientation for G-CSF-R by forming inter-
helical hydrogen bonds.
To determine the impact of the mutant G-CSF-RT617N 
on G-CSF sensitivity, we measured granulocytic prolifera-
tion and differentiation from CD34+ cells in in vitro experi-
ments. In the presence of stem cell factor (SCF) and G-CSF, 
proliferation was not significantly different between normal 
subjects and affected patients (patients 7 and 15). In contrast, 
SCF alone induced survival of control CD34+ cells, whereas 
it elicited proliferation (4.3-fold) on patient cells (Fig. 1 C). We 
also observed a hypersensitivity to G-CSF of patient CD34+ 
cells (Fig. 1 D) that was confirmed by clonogenic assays in 
methylcellulose (Fig. S2). Moreover, when CD34+ cells from 
normal subjects and affected individuals were grown in the 
presence of G-CSF, cells differentiated into mature granulo-
cytes, as indicated by cytological examination (Fig. 1 E). 
In contrast, in the presence of SCF alone, only cells from   
patients acquired the terminal granulocytic CD11b antigen 
(Fig. S3) and matured into neutrophilic polymorphs (Fig. 1 E). 
Collectively, these results show that mutant G-CSF-RT617N 
induces a G-CSF–independent granulocytic proliferation   
and differentiation.
cells/mm3). In the peripheral blood, a 3- to 20-fold increase 
in the percentage of circulating CD34+ cells was observed 
(Table I). The BM of two analyzed affected individuals con-
tained an increase in granulocyte precursors without an ex-
cess of blasts. The karyotype was normal; Bcr-Abl transcripts 
and JAK2V617F were not detected. All affected patients ex-
cept patient 15 had no clinical symptoms.
Based on the autosomal-dominant pattern of inheritance 
of the disorder and the high level of blood CD34+ cells, we 
tested the hypothesis that neutrophilia in this family resulted 
from activation of the G-CSF-R signaling. Because G-CSF 
concentration in the serum (two patients studied) was below 
the detection limit (<39 pmol/ml), we sequenced the CSF3R 
gene. We found a heterozygous C-to-A substitution at nu-
cleotide 2,088 that leads to a threonine-to-asparagine substi-
tution (T617N; Fig. 1 B). This heterozygous point mutation 
was observed in the 12 affected individuals but not in the 4 
healthy family members, and was segregated with the neutro-
philia (Fig. 1 A). Moreover, the mutation was found in all 
generations and in as many affected men as women. Finally, 
the mutation was transmitted with an autosomal-dominant pat-
tern of inheritance with complete penetrance. The CSF3RT617N 
mutation has already been described as an activating mutation 
found in 2 out of 555 patients with acute myeloid leukemia 
(Forbes et al., 2002). In these two cases, the mutation was   
acquired  because  it  disappeared  after  complete  remission 
achievement and was not detected at relapse (Forbes et al., 
2002). This last result demonstrates that the CSF3RT617N mu-
tation was a secondary event in the leukemic process. We 
studied whether this mutation could be found in sporadic 
cases of unexplained neutrophilia and investigated 40 cases by 
allele-specific PCR, but we did not find any other positive 
case suggesting that this activating mutation is rare.
The G-CSF-RT617N mutation is located in the transmem-
brane (TM) domain of the receptor, analogously to the MPLS505N 
Table I.  Laboratory hematological values from the family members
Numbers Age WBCs  
(per mm3)
Neutrophils  
(per mm3)
Hemoglobin Platelets  
(per mm3)
Circulating CD34+  
(per ml)
Circulating CD34+ Splenomegaly
yr g/dl %
1 70 14,700 11,000 13.7 157,000 NS NS NS 
2 80 15,900 13,900 14.2 268,000 NS NS Yes
4 46 27,100 21,510 13.8 278,000 NS NS Yes
5 40 29,100 20,370 14.2 290,000 NS NS NS 
6 35 20,400 15,700 12 267,000 NS NS NS
7 45 27,600 22,900 13.5 238,000 3,700 0.02 Yes
9 46 7,800 3,510 14.4 339,000 NS NS NS 
10 19 14,900 9,700 14.7 208,000 NS NS NS
12 13 20,600 15,500 13.3 347,000 NS NS NS
13 11 21,100 14,300 13.1 474,000 NS NS NS 
14 8 21,600 18,100 12.4 278,000 NS NS NS 
15 20 32,800 22,300 12.8 103,000 292,000 1.29 Yes
16 11 30,400 23,700 12.9 263,000 2,800 0.01 Yes
NS, not studied.1704 A HEREDITARY CSF3R MUTATION | Plo et al.
the empty vector (Migr), and engrafted the infected cells into 
irradiated hosts. Mice transplanted with cells expressing the 
mutant G-CSF-RT617N developed neutrophilia and displayed 
a high percentage of Gr-1+ granulocytes both in blood (33% 
in T617N vs. 15% in WT) and spleen (31% in T617N vs. 6% 
in WT; Fig. 3, A, B, E, and F), whereas the percentage of 
granulocytes in BM was only slightly affected (Fig. 3, C and D). 
An increase in B220+ B cells was also observed in the spleen, 
which may be caused by an increase in lymphopoiesis medi-
ated by the ectopic expression of the G-CSF-RT617N after 
retroviral transduction in hematopoietic stem cells (HSCs). 
Alternatively, this might be related to cytokine release in the 
spleen by the granulocytic precursors. All CSF3RT617N mice 
developed splenomegaly (Fig. 3 G). These data demonstrate 
that the T617N mutation in the G-CSF-R is at the origin of 
the neutrophilia observed in patients. To directly assess the 
consequences of this mutation on human HSCs, we per-
formed xenotransplantation in irradiated NOG mice of CD34+ 
To investigate the effects of the T617N mutation on   
G-CSF-R signaling, CD34+ cells isolated from normal do-
nors or patients were first deprived of cytokines, and then 
stimulated with G-CSF for various periods of time and sub-
jected to Western blot analysis using specific antibodies. In-
terestingly, patient cells exhibited constitutive phosphorylation 
of JAK2, STAT3, AKT, and ERK. After G-CSF stimula-
tion, JAK2, STAT3, STAT5, ERK, and AKT were rapidly 
and transiently activated in cells from normal donors, whereas 
phosphorylation was much more potent and sustained in 
cells from patients (Fig. 1 F). In addition, a specific JAK2 in-
hibitor abrogated constitutive and G-CSF–induced activa-
tion, suggesting that the mechanism of neutrophilia was 
JAK2 dependent, reminiscent of JAK2V617F MPD.
We next infected mouse lineage (Lin) BM cells with a 
retrovirus containing CSF3Rwt or CSF3RT617N mutation or 
Figure 2.  Computational searches of wild-type and T617N G-CSF-R 
dimers. (A) Molecular structure of the helix dimer of the T617N mutant 
having the overall lowest energy in the computational searches. The helices 
have a left-handed crossing angle and an axial separation of 10.5 Å. The 
interfacial amino acids are highlighted. (B) Plot of the helix interaction 
energies in the wild-type (black) and T617N (red) TM helix dimers with axial 
separations of 10.5 Å. In the wild-type G-CSF-R, the dominant interaction 
is a direct Thr617–Thr617 hydrogen bond between side chain hydroxyl 
groups. In contrast, there are several strong stabilizing interactions in the 
mutant. The Asn amide side chain forms hydrogen bonds to the thiol side 
chain of Cys620. Trp624 forms stabilizing van der Waals contacts with the 
opposing helix; the indole NH is also able to form an interhelical H bond 
with Cys620. The total interaction energies were very similar for the lowest 
energy T617N dimers in computational searches at 10 Å (80.6 kcal/mol) 
and 10.5 Å (81.0 kcal/mol). (C) Cross section of the T617N helix dimer 
showing hydrogen-bonding interactions involving Thr617 and Cys620. The 
axial separation is 10.5 Å. (D) Cross section of the T617N helix dimer with 
an axial separation of 11 Å stabilized by interhelical interactions between 
Asn617 side chains and between Asn617 and Cys618. The overall interac-
tion energies were generally higher at longer interhelical separations for 
both the wild-type and mutant dimers, although the T617N dimers were 
consistently lower in energy than those of the wild-type dimers because of 
the ability of Asn617 to form interhelical hydrogen bonds.
Figure 3.  CSF3RT617N mutation yields to MPD in the mouse BM 
transplant model. BM cells were collected from C57/B6 SJL (CD45.2) 
mice 2 d after 5-fluorouracil treatment. Lin cells were purified; cultured 
for 2 d with IL-3, SCF, IL-6, and TPO; infected twice with the viral par-
ticles containing empty vector (Migr), CSF3Rwt, or CSF3RT617N; and finally 
injected intravenously into lethally irradiated (825 rad) C57BL6 (CD45.1) 
mice. After 5 wk, mice were sacrificed and the total number of cells (A, C, 
and E) or the percentage of cells (B, D, and F) including granulocytes  
(Gr-1+), B lymphocytes (B220+), or T lymphocytes (CD3+) was measured  
in CD45.2+ donor mouse cells in the blood (A and B), BM (C and D), and 
spleen (E and F). (G) Spleen from Migr-engrafted (I), CSF3Rwt-engrafted 
(II), and CSF3RT617N-engrafted (III) mice. The results are the means ± SD of 
four mice of each group from two independent experiments. *, P < 0.05 
compared with Migr-engrafted mice.JEM VOL. 206, August 3, 2009  1705
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but also induces a mobilization of hematopoietic progenitors. 
Thus, in contrast to the truncating mutations found in severe 
congenital neutropenia, the CSF3RT617N mutation does not 
confer a major HSC-proliferative advantage but rather in-
creases myeloid differentiation (McLemore et al., 1998; Liu 
et al., 2008).
In conclusion, the family described in this report is the first 
case of germline CSF3R mutation leading to a chronic neutro-
philia and mobilization of hematopoietic progenitors, a phe-
notype similar to that induced by administration of rhG-CSF. 
The  T617N  TM  mutation  induces  both  proliferation  and 
granulocytic differentiation. Progression to a myelodysplastic 
syndrome (RAEB I) malignant hemopathy was observed on 1 
out of 12 affected patients. The precise role of the acquired 
CSF3R mutations found in severe congenital neutropenia is 
not completely resolved. Nevertheless, their association with 
leukemic  progression  is  increasingly  strong  (Germeshausen   
et al., 2007; Liu et al., 2008). Therefore, more investigations are 
necessary to know if CSF3RT617N mutation predisposes to ma-
lignant myeloid hemopathies.
MATERIALS AND METHODS
Patient cells. Blood samples from patients, normal subjects, and G-CSF–
mobilized patients were collected after informed consent was obtained. The 
study was approved by the Local Research Ethics Committee from the Hôtel-
Dieu and the Henri Mondor hospitals, and informed consent was obtained 
from each patient in accordance with the Declaration of Helsinki.
Purification and in vitro differentiation of CD34+ cells. Mononuclear 
cells were separated over a Ficoll density gradient, and CD34+ cells were pu-
rified by a double-positive magnetic cell sorting system (AutoMACS; Milte-
nyi  Biotec)  according  to  manufacturer’s  recommendations.  CD34+  cells 
were either plated for 15 d in methylcellulose (StemCell Technologies Inc.) 
in the presence of 25 ng/ml SCF and G-CSF, or amplified for 21 d in granu-
locytic conditions in serum-free liquid medium containing IMDM with 
penicillin/streptomycin/glutamine, -thioglycerol, BSA, a mixture of soni-
cated lipids, and insulin-transferrin in the presence of recombinant human 
cytokines (25 ng/ml SCF and 20 ng/ml G-CSF).
Western blot analysis. After purification, CD34+ cells were deprived in 
IMDM alone for 4 h in the presence or not of JAK2 inhibitor (AZD1480) at 
1 µM. AZD1480 was a gift from AstraZeneca (Waltham, MA). Cells were 
stimulated by 20 ng/ml G-CSF for different intervals, washed in PBS, and 
lysed in denaturing loading dye buffer. Western blot analysis was performed 
using conventional techniques using anti-Jak2 (pY1007/1008), anti-STAT3 
(pY705), anti-STAT5 (pY705), anti-ERK p42-p44 (T202/Y204), and anti-
AKT (S473) antibodies (Cell Signaling Technology), and anti–-actin anti-
bodies. Antibodies were visualized using the enhanced chemoluminescence 
detection kit (GE Healthcare).
DNA sequencing. Genomic DNAs were isolated from mononuclear cells 
or granulocytes according to standard procedures. Each of the 17 exons of the 
CSF3R gene (available from GenBank/EMBL/DDBJ under accession no. 
M59820) was amplified using standard PCR conditions from 300 ng of ge-
nomic DNA and primer sequences derived from flanking intronic sequences. 
PCR products were filtration purified (Multiscreen PCR; Millipore), sequenced 
using the BigDye Terminator cycle sequencing ready reaction kit (Applied 
Biosystems) according to the manufacturer’s protocol, and analyzed on an 
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
Generation of CSF3R mutant retroviruses and in vivo reconstitu-
tion of mouse hematopoietic system. A human hemagglutinin-tagged 
cells isolated either from the blood of patient 15 or from a 
G-CSF–mobilized normal donor. At week 15 after trans-
plant, the level of engraftment was measured by the percent-
age of human CD45+ cells in mouse blood, BM, spleen, and 
thymus. Levels of chimerism were lower in the four organs 
studied when patient CD34+ cells were injected compared 
with control cells (Fig. 4 A). Conversely, myeloid cells rep-
resented the predominant population in the blood, BM, and 
spleen of mice transplanted with patient CD34+ cells (Fig. 4 B), 
whereas B cells were prevalent with control cells (Fig. 4 C), 
as previously described (Bhatia et al., 1997; Ito et al., 2002; 
Matsumura et al., 2003). This skewed differentiation of HSCs 
to myeloid differentiation in immunodeficient mice has pre-
viously been described in MPDs (James et al., 2008). The 
frequency of human myeloid progenitors found among the 
CD45+ in the BM of mice engrafted with patient cells was 
increased in comparison to control cells. Moreover, a marked 
increase in the content of hematopoietic progenitors was ob-
served in the blood of patient cell–engrafted mice (Fig. 4 D). 
Collectively, these results show that G-CSF-RT617N mutant 
not only skews cells to myeloid differentiation in NOG mice 
Figure 4.  CSF3RT617N mutation yields to MPD in the xenotrans-
plantation model. CD34+ cells from normal subjects or from patients 
were intravenously injected into NOG mice and sacrificed at 15 wk. Flow 
cytometry analysis of human cell engraftment shows the percentage of 
human CD45+ cells (A) and percentage of B (CD19+) and myeloid (CD33+) 
cells (B and C) among CD45+ cells in the peripheral blood, BM, spleen, and 
thymus. The results are the means ± SD of four mice for donors and  
patient from two independent experiments. (D) Peripheral blood progenitors 
among CD45+ cells from donor- or patient-engrafted mice.1706 A HEREDITARY CSF3R MUTATION | Plo et al.
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retroviral vector. Mutagenesis reactions for human CSF3R were performed 
using the QuickChange site-directed mutagenesis kit (Agilent Technologies). 
All constructs were verified by sequencing.
Vesicular stomatitis virus glycoprotein–pseudotyped viral particles of 
pMIGR-IRES-GFP  (empty  vector),  pMIGR-CSF3R-IRES-GFP,  and 
pMIGR-T617N-CSF3R-IRES-GFP were produced into the 293 EBNA 
cells. Ecotropic virus-producing cell lines were generated from infection of 
the GP+E-86 packaging cell line (supplied by A. Bank, Columbia Univer-
sity, New York, NY) with concentrated virus supernatants.
BM (Lin) cells were collected from C57BL/6 SJL (CD45.2) mice 
(Charles River Laboratories) 2 d after 5-fluorouracil treatment. Lin cells 
were purified; cultured for 2 d with IL-3, SCF, IL-6, and TPO; and infected 
twice with the viral particles and finally injected intravenously into lethally 
irradiated (8.25 Gy) C57BL/6 (CD45.1) mice.
Hemoglobin, mean corpuscular volume, hematocrit, RBC, platelet, and 
WBC counts, and the lymphocyte/granulocyte ratio were determined using 
an automated counter (MS9; Schloessing Melet) on blood collected from the 
retro-orbital plexus in citrated tubes. BM cells were removed by flushing two 
femurs and two tibias. Spleens were weighed and single-cell suspensions 
were prepared. Differential cell counts were performed after May-Grün-
wald-Giemsa staining of blood smears or spleen and BM cell cytospins.
NOG mice repopulation assays. 24 h before transplantation, 6–8-wk-old 
NOD/SCID/c/ (NOG) mice, provided by M. Ito (Central Institute for 
Experimental Animals, Kawasaki, Japan), were sublethally irradiated (3 Gy) as 
previously described (Ito et al., 2002). CD34+ cells from G-CSF–mobilized 
donors or from patients were intravenously injected into NOG mice without 
any administration of cytokines. Human cell engraftment was assessed by 
flow cytometry by measuring human leukocytes (CD45+). Blood was lysed. 
BM cells were removed by flushing both femurs. Spleens were weighed and 
single-cell suspensions were prepared. NOG mice were bred in our patho-
gen-free breeding facility (Service Centrale d’Expérimentation Animale).
For progenitor assay, 50 µl of peripheral blood and BM from mice en-
grafted with donors or patient cells were seeded in methylcellulose, and pro-
genitors were counted after 14 d in the presence of a cocktail of cytokines (100 
IU/ml IL-3, 25 ng/ml SCF, 3 IU/ml erythropoietin, and 5 ng/ml GM-CSF). 
The number of human colonies was normalized to 100,000 human cells.
FACS analysis. Flow cytometry was used to determine GFP expression and cell 
content of blood, BM, and spleen cells with appropriate PE- or allophycocyanin-
conjugated antibodies (anti–human CD45, anti-CD45.1, anti-CD45.2, 
anti-CD19, anti-CD3, anti-CD33, anti-CD11b, anti-CD15, anti-CD14, 
anti-CD34, anti-CDB220, and anti–Gr-1 antibodies; BD) using a cytometer 
(FACSsort) with the Cell Quest software package (BD).
Modeling the effect of the T617N mutation on G-CSFR structure 
and dimerization. Computational searches for low energy dimer confor-
mations were performed using the program CHI (Adams et al., 1996). Ca-
nonical helices were constructed from the TM sequence of the G-CSF-R 
(IILGLFGLLLLLTCLCGTAWLCC). Low energy conformations of helix 
dimers were searched by rotating each helix through rotation angles 1 
and 2 from 0–360°, with a sampling size of 45° for axial separations be-
tween TM helices of 9.5, 10, 10.5, 11, and 11.5 Å, as described previously 
(Seubert et al., 2003).
Online supplemental material. Fig. S1 shows qRT-PCR of EVI1 using the 
Taqman gene expression master mix (Applied Biosystems) and specific primers, 
as previously described (Vinatzer et al., 2003). In Fig. S2, CD34+ progenitors 
cells either from controls or from patients were cultured in methylcellulose in 
the presence of SCF and various doses of G-CSF, or in the presence of SCF 
alone. Granulocytic colonies were counted 15 d later. Alternatively, cells from 
patients were cultured with or without 1 µM AZD1480. Fig. S3 indicates granu-
locytic differentiation using FACS analysis using anti-CD34, anti-CD15, anti-
CD14, and anti-CD11b antibodies. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20090693/DC1.JEM VOL. 206, August 3, 2009  1707
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